Dr. Ochoa-Bayona's research centers on developing better therapies for patients suffering from blood cancers such as multiple myeloma, acute myeloid leukemia (AML), and light chain amyloidosis. He studies the use of stem cells and chemotherapy drugs to improve treatment effectiveness while minimizing harmful side effects. For instance, he explores how different types of stem cell collections can enhance the strength of CAR-T cells, which are engineered to attack cancer cells, and looks into the impacts of various chemotherapy doses on post-transplant complications in AML and myelodysplastic syndromes.
Key findings
Patients with multiple myeloma received CAR-T cells from earlier stem cell samples, leading to significantly stronger and more effective cells.
In a study on AML and myelodysplastic syndromes, a lower dose of melphalan (100 mg/m²) reduced gastrointestinal toxicity to 40.3% compared to 67.8% with a higher dose (140 mg/m²) and also decreased rates of graft-versus-host disease.
Patients with light chain amyloidosis showed a survival rate of 70.6% with bortezomib and dexamethasone vs. 84.6% with the addition of cyclophosphamide, but the difference was not statistically significant.
Using paclitaxel for mobilizing blood stem cells after previous treatment failures increased the number of stem cells collected to 1.53 million cells per kg, compared to 0.79 million cells per kg with prior treatments, helping 73% of patients to proceed to stem cell transplant.
Frequently asked questions
Does Dr. Ochoa-Bayona study multiple myeloma?
Yes, Dr. Ochoa-Bayona studies treatments for multiple myeloma and has worked on improving CAR-T cell therapies for this condition.
What treatments has Dr. Ochoa-Bayona researched?
He has researched CAR-T cell therapies, chemotherapy regimens involving melphalan, fludarabine, bortezomib, dexamethasone, and cyclophosphamide, and methods to mobilize stem cells in blood cancer patients.
Is Dr. Ochoa-Bayona's work relevant to patients with acute myeloid leukemia?
Yes, his research on chemotherapy dosages and their effects on side effects and post-transplant complications is particularly relevant for patients undergoing treatment for AML.
What improvements have been found in Dr. Ochoa-Bayona's research?
His studies have shown that lower doses of certain chemotherapy drugs can significantly reduce side effects, and the timing of stem cell collection affects the efficacy of CAR-T cell therapies.
How does Dr. Ochoa-Bayona's research help patients with light chain amyloidosis?
His work clarifies the effectiveness of treatment options, helping patients and healthcare providers make informed decisions about therapies involving bortezomib and dexamethasone.
Publications in plain English
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma.
2025
Molecular therapy : the journal of the American Society of Gene Therapy
Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J +14 more
Plain English This study looked at how different types of stem cell samples can affect the production of CAR-T cells for treating multiple myeloma, a type of blood cancer. Researchers found that cells collected before a stem cell transplant created stronger CAR-T cells compared to those collected later for commercial use. These earlier samples led to CAR-T cells that expanded better, produced more vital proteins, and had improved energy function, showing they could be more effective in fighting the disease.
Who this helps: This helps patients with multiple myeloma by improving CAR-T cell therapy outcomes.
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
2024
Transplantation and cellular therapy
Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R +13 more
Plain English This study looked at the effects of different doses of melphalan, a chemotherapy drug, when combined with fludarabine for patients undergoing stem cell transplants for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Researchers found that patients who received a lower dose of melphalan (100 mg/m²) experienced significantly less gastrointestinal toxicity (40.3% compared to 67.8%) and lower rates of graft-versus-host disease (GVHD) than those who received a higher dose (140 mg/m²). These findings highlight the importance of using a lower dose of melphalan to reduce side effects and complications after transplant.
Who this helps: Patients undergoing stem cell transplants for AML and MDS.
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
2022
Clinical lymphoma, myeloma & leukemia
Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D +8 more
Plain English This study looked at the effects of adding a drug called cyclophosphamide to a treatment regimen of bortezomib and dexamethasone for patients newly diagnosed with light chain amyloidosis. Among 136 patients, those receiving just bortezomib and dexamethasone had a 70.6% survival rate over two years, while those on the combination treatment had an 84.6% survival rate, but the difference was not significant. Essentially, adding cyclophosphamide did not lead to better outcomes for these patients.
Who this helps: This helps patients with light chain amyloidosis and their healthcare providers by clarifying treatment options.
Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen.
Plain English This study looked at how effective the combination of two drugs, paclitaxel and G-CSF, is at mobilizing blood stem cells in patients with blood cancers who did not respond well to earlier treatments. Out of 26 adults treated, those who received paclitaxel produced significantly more stem cells (1.53 million cells per kg) compared to their previous treatment (0.79 million cells per kg). Additionally, 73% of the patients were able to go on to receive a stem cell transplant, making this approach a promising option for those who struggled with earlier methods.
Who this helps: This benefits patients with blood cancers who need effective treatment options after previous therapies have failed.